Consolidated figures · ₹ crore
| ₹ Cr | Mar 2025 | Mar 2026 |
|---|---|---|
| 502 | 642 | |
| COGS | — | 227 |
| Gross profit | — | 415 |
| 312 | 193 | |
| 190 | 222 | |
| OPM % | 37.8% | 34.6% |
| Depreciation | 11 | 15 |
| Interest | 6 | 8 |
| 9 | 29 | |
| Profit before tax | 183 | 228 |
| Tax | 44 | 54 |
| Tax % | 24.1% | 23.6% |
| 139 | 174 | |
| PAT margin % | 27.6% | 27.1% |
| EPS (₹) | 12.8 | 15.5 |
| EPS adjusted (₹) | 14.3 | 15.3 |
| 0% | 9.7% | |
| Annual report | — | Annual report for Mar 2026 |
| ₹ Cr | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 10 | 11 |
| Reserves | 481 | 872 |
| Minority interest | 2 | 15 |
| 135 | 148 | |
| 89 | 129 | |
| Total equity & liabilities | 717 | 1,175 |
| 246 | 292 | |
| CWIP | 88 | 178 |
| Investments | 0 | 0 |
| 383 | 704 | |
| Total assets | 717 | 1,175 |
| ₹ Cr | Mar 2026 |
|---|---|
| 70 | |
| -327 | |
| 247 | |
| Net cash flow | -10 |
| Free cash flow | -49 |
| CFO / Operating profit % | 31.3% |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Pharmaceutical, Food and Nutrition | 362.64 | 113.52 | 727.21 | 217.88 | 509.33 | 22.29 |
| Speciality Ingredients | 279.62 | 93.58 |
| 443.74 |
| 48.51 |
| 395.23 |
| 23.68 |
| Inter Segment Revenue | 8.47 | 0 | 0 | 0 | — | — |
₹ crore by fiscal year